The pharmaceutical company GlaxoSmithKline (GSK), has received approval for their lupus drug Benlysta by the advisory panel for the Food and Drug Administration.
As a result, shares in the global pharma company surged 29.5p to 1234p. Benlysta was developed in partnership with American biotech Human Genome Sciences and are forecast to oar to £1.4bn by 2014.
GSK is also planning to withdraw their diabetes drug Avandia from Europe and is restricting sales in the US as the dug was found to increase the risk of heart attack.
Are you looking for a position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.